Certara (NASDAQ:CERT) Rating Lowered to Hold at Wall Street Zen

Certara (NASDAQ:CERT) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

CERT has been the topic of several other research reports. Rothschild & Co Redburn set a $10.00 price objective on Certara in a report on Friday, November 21st. KeyCorp reduced their target price on Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. BMO Capital Markets began coverage on shares of Certara in a report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price target for the company. Finally, Stephens reduced their price target on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.82.

Certara Stock Down 0.7%

NASDAQ CERT opened at $6.62 on Friday. Certara has a twelve month low of $6.45 and a twelve month high of $15.69. The stock has a market cap of $1.05 billion, a PE ratio of 94.57 and a beta of 1.47. The firm has a 50-day simple moving average of $8.77 and a 200 day simple moving average of $10.12. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09.

Hedge Funds Weigh In On Certara

A number of institutional investors have recently bought and sold shares of CERT. Squarepoint Ops LLC increased its position in Certara by 75.3% during the 4th quarter. Squarepoint Ops LLC now owns 78,546 shares of the company’s stock worth $692,000 after buying an additional 33,730 shares during the period. Landscape Capital Management L.L.C. bought a new position in Certara during the 4th quarter worth approximately $193,000. Dixon Mitchell Investment Counsel Inc. boosted its holdings in shares of Certara by 78.5% during the 4th quarter. Dixon Mitchell Investment Counsel Inc. now owns 1,546,299 shares of the company’s stock worth $13,623,000 after buying an additional 679,919 shares in the last quarter. Barclays PLC raised its stake in Certara by 28.9% during the 4th quarter. Barclays PLC now owns 38,816 shares of the company’s stock worth $342,000 after buying an additional 8,712 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of Certara by 8.7% during the fourth quarter. Marshall Wace LLP now owns 798,182 shares of the company’s stock valued at $7,032,000 after buying an additional 64,153 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.